960 related articles for article (PubMed ID: 15464333)
1. Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study.
Ghofrani HA; Voswinckel R; Reichenberger F; Olschewski H; Haredza P; Karadaş B; Schermuly RT; Weissmann N; Seeger W; Grimminger F
J Am Coll Cardiol; 2004 Oct; 44(7):1488-96. PubMed ID: 15464333
[TBL] [Abstract][Full Text] [Related]
2. Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension.
Michelakis ED; Tymchak W; Noga M; Webster L; Wu XC; Lien D; Wang SH; Modry D; Archer SL
Circulation; 2003 Oct; 108(17):2066-9. PubMed ID: 14568893
[TBL] [Abstract][Full Text] [Related]
3. Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension.
Montani D; Chaumais MC; Savale L; Natali D; Price LC; Jaïs X; Humbert M; Simonneau G; Sitbon O
Adv Ther; 2009 Sep; 26(9):813-25. PubMed ID: 19768639
[TBL] [Abstract][Full Text] [Related]
4. Pharmacology and drug interaction effects of the phosphodiesterase 5 inhibitors: focus on alpha-blocker interactions.
Kloner RA
Am J Cardiol; 2005 Dec; 96(12B):42M-46M. PubMed ID: 16387566
[TBL] [Abstract][Full Text] [Related]
5. Binding of tritiated sildenafil, tadalafil, or vardenafil to the phosphodiesterase-5 catalytic site displays potency, specificity, heterogeneity, and cGMP stimulation.
Blount MA; Beasley A; Zoraghi R; Sekhar KR; Bessay EP; Francis SH; Corbin JD
Mol Pharmacol; 2004 Jul; 66(1):144-52. PubMed ID: 15213306
[TBL] [Abstract][Full Text] [Related]
6. Erectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafil--review of the literature.
Gresser U; Gleiter CH
Eur J Med Res; 2002 Oct; 7(10):435-46. PubMed ID: 12435622
[TBL] [Abstract][Full Text] [Related]
7. Comparative relaxing effects of sildenafil, vardenafil, and tadalafil in human corpus cavernosum: contribution of endogenous nitric oxide release.
Toque HA; Priviero FB; Teixeira CE; Claudino MA; Baracat JS; Fregonesi A; De Nucci G; Antunes E
Urology; 2009 Jul; 74(1):216-21. PubMed ID: 19371941
[TBL] [Abstract][Full Text] [Related]
8. Absence of clinically important HERG channel blockade by three compounds that inhibit phosphodiesterase 5--sildenafil, tadalafil, and vardenafil.
Dustan Sarazan R; Crumb WJ; Beasley CM; Emmick JT; Ferguson KM; Strnat CA; Sausen PJ
Eur J Pharmacol; 2004 Oct; 502(3):163-7. PubMed ID: 15476742
[TBL] [Abstract][Full Text] [Related]
9. Phosphodiesterase 5 inhibitors for erectile dysfunction.
Setter SM; Iltz JL; Fincham JE; Campbell RK; Baker DE
Ann Pharmacother; 2005; 39(7-8):1286-95. PubMed ID: 15941818
[TBL] [Abstract][Full Text] [Related]
10. High biochemical selectivity of tadalafil, sildenafil and vardenafil for human phosphodiesterase 5A1 (PDE5) over PDE11A4 suggests the absence of PDE11A4 cross-reaction in patients.
Weeks JL; Zoraghi R; Beasley A; Sekhar KR; Francis SH; Corbin JD
Int J Impot Res; 2005; 17(1):5-9. PubMed ID: 15538396
[TBL] [Abstract][Full Text] [Related]
11. Phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction in patients with diabetes mellitus.
Vickers MA; Satyanarayana R
Int J Impot Res; 2002 Dec; 14(6):466-71. PubMed ID: 12494279
[TBL] [Abstract][Full Text] [Related]
12. Sildenafil is a pulmonary vasodilator in awake lambs with acute pulmonary hypertension.
Weimann J; Ullrich R; Hromi J; Fujino Y; Clark MW; Bloch KD; Zapol WM
Anesthesiology; 2000 Jun; 92(6):1702-12. PubMed ID: 10839922
[TBL] [Abstract][Full Text] [Related]
13. Prescribing all phosphodiesterase 5 inhibitors to a patient with erectile dysfunction--a realistic and feasible option in everyday clinical practice--outcomes of a simple treatment regime.
Ströberg P; Hedelin H; Ljunggren C
Eur Urol; 2006 May; 49(5):900-7; discussion 907. PubMed ID: 16564126
[TBL] [Abstract][Full Text] [Related]
14. Sildenafil for primary and secondary pulmonary hypertension.
Watanabe H; Ohashi K; Takeuchi K; Yamashita K; Yokoyama T; Tran QK; Satoh H; Terada H; Ohashi H; Hayashi H
Clin Pharmacol Ther; 2002 May; 71(5):398-402. PubMed ID: 12011826
[TBL] [Abstract][Full Text] [Related]
15. Optimization of purine based PDE1/PDE5 inhibitors to a potent and selective PDE5 inhibitor for the treatment of male ED.
Boyle CD; Xu R; Asberom T; Chackalamannil S; Clader JW; Greenlee WJ; Guzik H; Hu Y; Hu Z; Lankin CM; Pissarnitski DA; Stamford AW; Wang Y; Skell J; Kurowski S; Vemulapalli S; Palamanda J; Chintala M; Wu P; Myers J; Wang P
Bioorg Med Chem Lett; 2005 May; 15(9):2365-9. PubMed ID: 15837326
[TBL] [Abstract][Full Text] [Related]
16. Effect of the phosphodiesterase 5 inhibitors sildenafil, tadalafil and vardenafil on rat anococcygeus muscle: functional and biochemical aspects.
Toque HA; Priviero FB; Zemse SM; Antunes E; Teixeira CE; Webb RC
Clin Exp Pharmacol Physiol; 2009 Apr; 36(4):358-66. PubMed ID: 18986324
[TBL] [Abstract][Full Text] [Related]
17. A 46-amino acid segment in phosphodiesterase-5 GAF-B domain provides for high vardenafil potency over sildenafil and tadalafil and is involved in phosphodiesterase-5 dimerization.
Blount MA; Zoraghi R; Ke H; Bessay EP; Corbin JD; Francis SH
Mol Pharmacol; 2006 Nov; 70(5):1822-31. PubMed ID: 16926278
[TBL] [Abstract][Full Text] [Related]
18. Acute hemodynamic effects of intravenous sildenafil citrate in congestive heart failure: comparison of phosphodiesterase type-3 and -5 inhibition.
Botha P; Parry G; Dark JH; Macgowan GA
J Heart Lung Transplant; 2009 Jul; 28(7):676-82. PubMed ID: 19560695
[TBL] [Abstract][Full Text] [Related]
19. Role of oral sildenafil in severe pulmonary arterial hypertension: clinical efficacy and dose response relationship.
Garg N; Sharma MK; Sinha N
Int J Cardiol; 2007 Sep; 120(3):306-13. PubMed ID: 17174417
[TBL] [Abstract][Full Text] [Related]
20. Effects of phosphodiesterase 5 inhibitor on pulmonary vascular reactivity in the fetal lamb.
Jaillard S; Larrue B; Deruelle P; Delelis A; Rakza T; Butrous G; Storme L
Ann Thorac Surg; 2006 Mar; 81(3):935-42. PubMed ID: 16488698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
